Analysts think CATX stock price could increase by 342%
Dec 03, 2024, 12:25 PM
-23.13%
What does CATX do
Perspective Therapeutics, based in Seattle, is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment using the alpha-emitting isotope 212Pb. Their programs for melanoma and neuroendocrine tumors are in Phase I/IIa trials.
12 analysts think CATX stock price will increase by 342.41%. The current median analyst target is $18.36 compared to a current stock price of $4.15. The lowest analysts target is $6.06 and the highest analyst target is $25.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
